II. Indications
- Skin disorders
- Gastrointestinal disorders
- Helicobacter Pylori (part of quadruple therapy protocol)
- Tick Borne Illness
- Miscellaneous disorders
- Sexually Transmitted Disease
III. Precautions
- AAP now approves Doxycycline for ANY age up to 21 day duration (esp. Tick Borne Illness)
IV. Formulations
- Capsule (Doxycycline Monohydrate)
- Strengths: 50,75,100,150 mg (generics available)
- Tablet (Doxycycline Monohydrate)
- Strengths: 50,75,100,150 mg (generics available)
- Tablet (Doxycycline Hyclate)
- Strengths: 20,50,75,100,150 mg (generics available)
- Doxycyline Hyclate Delayed-Release (Doryx MPC)
- Expensive ($10/pill) formulated to by-pass the esophagus for less side effects
- Alternatively, take the doxycyline with 8 oz water and food
- (2016) Presc Lett 23(11)
V. Dosing: Adults (weight >45 kg)
- Typical dose: 100 mg orally twice daily
- Low doses, such as 50 mg daily, are often as effective for Acne Vulgaris
- Avoid substituting low-dose Doxycycline (Periostat, Oracea) products for systemic infections
- May substitute other Doxycycline salts
- Doxycycline hyclate (Vibramycin, Doryx)
- Doxycycline monohydrate (Monodox)
- (2013) Presc Lett 20(5):26
VI. Pregnancy
- All Trimesters - Category D
VII. Adverse Effects
- Photosensitivity
- Use sun protection (e.g. Sunscreen)
-
Pill Esophagitis
- Take with 8 ounces fluid
-
Drug-Induced Tooth Staining
- Compared with Tetracycline, Doxcycyline is unlikely to cause tooth staining in children, even under age 8 years.
- Frequency: Uncommon to rare
- Abdominal Pain
- Diarrhea
VIII. Drug Interactions
- Doxycycline Decreases Absorption Of Other Substances
- Doxycycline Level Decreased By Other Substance
IX. Pharmacokinetics
- Absorption: Not affected by food or milk intake (unlike Tetracycline)
- Peak Activity: >2.6 hours
- Half Life: 18-22 hours
- Primary Elimination: Renal (>40%)
- Other Elimination: Hepatic
X. Resources
- Moses, Fpnotebook (accessed 10/3/2021)
- DailyMed (accessed 10/3/2021)
- DailyMed (accessed 10/3/2021)
Images: Related links to external sites (from Bing)
Related Studies
| doxycycline (on 5/17/2017 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| DOXYCYCLINE 25 MG/5 ML SUSP | Generic | $0.29 per ml |
| DOXYCYCLINE HYC DR 100 MG TAB | Generic | $8.83 each |
| DOXYCYCLINE HYCLATE 100 MG CAP | Generic | $0.49 each |
| DOXYCYCLINE HYCLATE 100 MG TAB | Generic | $0.63 each |
| DOXYCYCLINE HYCLATE 20 MG TAB | Generic | $0.36 each |
| DOXYCYCLINE HYCLATE 50 MG CAP | Generic | $0.59 each |
| DOXYCYCLINE IR-DR 40 MG CAP | Generic | $15.88 each |
| DOXYCYCLINE MONO 100 MG CAP | Generic | $0.42 each |
| DOXYCYCLINE MONO 100 MG TABLET | Generic | $0.50 each |
| DOXYCYCLINE MONO 150 MG TABLET | Generic | $5.36 each |
| DOXYCYCLINE MONO 50 MG CAP | Generic | $0.31 each |
| DOXYCYCLINE MONO 50 MG TABLET | Generic | $0.44 each |
Ontology: Doxycycline (C0013090)
| Definition (CHV) | a kind of antibiotics |
| Definition (MSH) | A synthetic tetracycline derivative with similar antimicrobial activity. |
| Definition (NCI_NCI-GLOSS) | A drug used to treat many types of bacterial infections. It stops the growth of bacteria by keeping them from making proteins. It is a type of antibiotic. |
| Definition (NCI) | A synthetic, broad-spectrum tetracycline antibiotic exhibiting antimicrobial activity. Doxycycline binds to the 30S ribosomal subunit, possibly to the 50S ribosomal subunit as well, thereby blocking the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This leads to an inhibition of protein synthesis. In addition, this agent has exhibited inhibition of collagenase activity. |
| Definition (PDQ) | A synthetic, broad-spectrum tetracycline antibiotic exhibiting antimicrobial activity. Doxycycline binds to the 30S ribosomal subunit, possibly to the 50S ribosomal subunit as well, thereby blocking the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This leads to an inhibition of protein synthesis. In addition, this agent has exhibited inhibition of collagenase activity. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42494&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42494&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C457" NCI Thesaurus) |
| Concepts | Antibiotic (T195) , Organic Chemical (T109) |
| MSH | D004318 |
| SnomedCT | 10504007, 372478003 |
| LNC | LP14992-9, MTHU002295 |
| English | Doxycycline, 2-Naphthacenecarboxamide, 4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-, (4S-(4alpha,4aalpha,5alpha,5aalpha,6alpha,12aalpha))-, doxycycline, DOXYCYCLINE, Doxycycline [Chemical/Ingredient], Alpha 6 Deoxyoxytetracycline, Alpha-6-Deoxyoxytetracycline, Doxycycline (product), Doxycycline (substance) |
| Swedish | Doxycyklin |
| Czech | doxycyklin |
| Finnish | Doksisykliini |
| Russian | VIBRAMITSIN, DOKSITSIKLIN, ВИБРАМИЦИН, ДОКСИЦИКЛИН |
| Italian | alfa-6-Deossi-ossitetraciclina, Doxiciclina |
| Croatian | DOKSICIKLIN |
| Polish | Doksycyklina, Wibramycyna |
| Japanese | ドキシサイクリン, 塩酸ドキシサイクリン |
| Norwegian | Doksycyklin |
| Spanish | doxiciclina (producto), doxiciclina (sustancia), doxiciclina, Doxiciclina |
| French | Doxycycline |
| German | Doxycyclin |
| Portuguese | Doxiciclina |
